See more : YaGuang Technology Group Company Limited (300123.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Gyre Therapeutics, Inc. (GYRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gyre Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Asukanet Co., Ltd. (2438.T) Income Statement Analysis – Financial Results
- Round Hill Music Royalty Fund Limited (RHM.L) Income Statement Analysis – Financial Results
- Addtech AB (publ.) (ADDT-B.ST) Income Statement Analysis – Financial Results
- Great Ajax Corp. (AJX) Income Statement Analysis – Financial Results
- VINTAGE COFFEE AND BEVERAGES L (VINCOFE.BO) Income Statement Analysis – Financial Results
Gyre Therapeutics, Inc. (GYRE)
About Gyre Therapeutics, Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.45M | 794.00K | 7.34M | 20.95M | 0.00 | 6.00K | 1.02M | 399.00K | 1.75M | 275.00K | 3.63M | 57.86M | 97.64M | 85.71M | 25.06M | 20.09M | 11.58M | 27.54M | 1.18M | 3.74M | 2.46M | 2.29M | 1.70M |
| Cost of Revenue | 4.64M | 798.00K | 7.38M | 9.16M | 43.86M | 21.47M | 12.85M | 10.56M | 5.96M | 5.27M | 6.56M | 0.00 | 0.00 | 0.00 | 691.00K | 749.00K | 715.42K | 457.25K | 480.93K | 198.45K | 743.00K | 244.00K | 0.00 |
| Gross Profit | 108.81M | -4.00K | -42.00K | 11.79M | -43.86M | -21.47M | -11.83M | -10.16M | -4.21M | -4.99M | -2.93M | 57.86M | 97.64M | 85.71M | 24.37M | 19.34M | 10.86M | 27.08M | 698.98K | 3.54M | 1.72M | 2.04M | 1.70M |
| Gross Profit Ratio | 95.91% | -0.50% | -0.57% | 56.26% | 0.00% | -357,800.00% | -1,161.98% | -2,545.36% | -240.46% | -1,815.27% | -80.68% | 100.00% | 100.00% | 100.00% | 97.24% | 96.27% | 93.82% | 98.34% | 59.24% | 94.69% | 69.77% | 89.33% | 100.00% |
| Research & Development | 13.78M | 13.04M | 68.89M | 52.98M | 43.86M | 21.47M | 12.85M | 11.56M | 5.96M | 19.50M | 38.84M | 49.09M | 95.22M | 64.55M | 40.18M | 40.98M | 34.62M | 21.79M | 24.25M | 22.77M | 18.18M | 16.24M | 8.15M |
| General & Administrative | 14.66M | 17.37M | 18.96M | 16.18M | 13.42M | 12.35M | 9.99M | 9.26M | 9.59M | 10.17M | 12.01M | 13.19M | 12.17M | 8.05M | 8.17M | 6.50M | 8.01B | 5.70B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 61.16M | 54.24M | 44.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.00B | -5.69B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.82M | 17.37M | 18.96M | 16.18M | 13.42M | 12.35M | 9.99M | 9.26M | 9.59M | 10.17M | 12.01M | 13.19M | 12.17M | 8.05M | 8.17M | 6.50M | 8.01M | 5.70M | 6.39M | 5.16M | 3.60M | 4.14M | 2.30M |
| Other Expenses | 86.44M | -517.00K | -78.00K | 568.00K | -46.00K | 1.65M | 261.00K | 86.00K | 0.00 | 318.00K | 518.00K | 1.04M | 0.00 | 0.00 | 51.28M | 32.01M | 27.33B | 16.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.04M | 30.40M | 87.85M | 69.16M | 57.28M | 33.83M | 22.84M | 20.82M | 15.55M | 29.67M | 50.85M | 62.28M | 107.38M | 72.60M | 64.70M | 47.48M | 42.63M | 27.48M | 30.64M | 27.93M | 21.78M | 23.05M | 10.45M |
| Cost & Expenses | 180.68M | 31.20M | 95.23M | 78.32M | 57.28M | 33.83M | 22.84M | 20.82M | 15.55M | 29.67M | 50.85M | 62.28M | 107.38M | 72.60M | 65.39M | 48.23M | 43.35M | 27.94M | 31.12M | 28.13M | 22.52M | 23.29M | 10.45M |
| Interest Income | 0.00 | 537.00K | 39.00K | 1.13M | 2.10M | 3.77M | 261.00K | 3.47M | 518.00K | 585.00K | 784.00K | 1.07M | 1.22M | 1.46M | 1.05M | 2.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 717.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.48M | 23.00K | 53.00K | 86.00K | 132.00K | 153.00K | 217.00K | 251.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 1.11M | 1.13M | 290.00K | 138.00K | 146.00K | 149.00K | 173.00K | 389.00K | 470.00K | 351.00K | 547.00K | 2.21M | 2.48M | 2.00M | 1.84M | 1.80M | 907.16K | 820.92K | 803.19K | 766.34K | 0.00 | 0.00 | 0.00 |
| EBITDA | 20.33M | 10.33M | -87.60M | -57.37M | -57.28M | -33.82M | -21.82M | -16.95M | -12.81M | -29.71M | -47.22M | -8.14M | -9.75M | 13.12M | -40.33M | -28.14M | -30.86M | 417.23K | -29.14M | -23.13M | -20.06M | -21.00M | -8.75M |
| EBITDA Ratio | 17.92% | -6,568.39% | -1,193.84% | -273.87% | 0.00% | -563,700.00% | -2,143.61% | -4,246.87% | -732.23% | -10,349.09% | -1,301.07% | -1.21% | -9.98% | 15.30% | -160.90% | -140.12% | -266.63% | 1.52% | -2,469.47% | -631.90% | -816.27% | -918.77% | -513.86% |
| Operating Income | -67.23M | -8.61M | -87.89M | -57.37M | -57.28M | -33.82M | -21.82M | -20.42M | -13.80M | -29.71M | -47.22M | -8.14M | -9.75M | 13.12M | -40.33M | -28.14M | -31.77M | -403.69K | -29.94M | -24.39M | -20.06M | -21.00M | -8.75M |
| Operating Income Ratio | -59.26% | -1,084.51% | -1,197.79% | -273.87% | 0.00% | -563,700.00% | -2,143.61% | -5,117.29% | -788.69% | -10,805.09% | -1,301.07% | -14.06% | -9.98% | 15.30% | -160.90% | -140.12% | -274.46% | -1.47% | -2,537.54% | -652.51% | -816.27% | -918.77% | -513.86% |
| Total Other Income/Expenses | -9.74M | 209.00K | -39.00K | 1.13M | 2.10M | 3.77M | 261.00K | 3.47M | -960.00K | 575.00K | 518.00K | 1.04M | 1.22M | 1.31M | 833.00K | 2.48M | 3.70B | -1.24B | 949.39K | 368.04K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -76.97M | -7.89M | -87.93M | -56.24M | -55.18M | -30.06M | -21.56M | -16.95M | -14.76M | -29.14M | -46.70M | -7.10M | -8.53M | 14.43M | -39.49M | -25.66M | -28.07B | -1.24B | 0.00 | -24.40M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -67.84% | -994.21% | -1,198.32% | -268.48% | 0.00% | -500,916.67% | -2,117.98% | -4,246.87% | -843.54% | -10,596.00% | -1,286.80% | -12.27% | -8.74% | 16.83% | -157.58% | -127.76% | -242,510.84% | -4,489.05% | 0.00% | -652.63% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 8.52M | 348.00K | -39.00K | -699.00K | -2.29M | 3.77M | -173.00K | 3.08M | 518.00K | 3.48M | 7.00K | -101.00K | -2.48M | 3.53M | -88.00K | -4.28M | -3.70M | -2.50M | -949.39K | -368.04K | 19.40M | 21.07M | 7.30M |
| Net Income | -92.93M | 2.30M | -87.93M | -55.54M | -52.89M | -30.06M | -21.56M | -16.95M | -14.76M | -32.62M | -46.71M | -7.00M | -8.53M | 10.90M | -39.40M | -25.66M | -28.07M | 2.10M | -28.99M | -24.03M | -19.40M | -21.07M | -7.30M |
| Net Income Ratio | -81.92% | 289.92% | -1,198.32% | -265.14% | 0.00% | -500,916.67% | -2,117.98% | -4,246.87% | -843.54% | -11,862.91% | -1,286.99% | -12.09% | -8.74% | 12.72% | -157.23% | -127.76% | -242.51% | 7.61% | -2,457.08% | -642.67% | -789.06% | -921.78% | -428.77% |
| EPS | -1.41 | 0.04 | -2.87 | -2.90 | -4.41 | -2.68 | -6.30 | -21.76 | -49.99 | -101.40 | -145.78 | -21.95 | -28.31 | 39.90 | -161.39 | -109.24 | -149.47 | -9.45 | -11.62K | -11.51K | -18.68K | -8.10K | -2.81K |
| EPS Diluted | -1.41 | 0.03 | -2.87 | -2.90 | -4.41 | -2.68 | -6.30 | -21.76 | -49.99 | -101.40 | -145.78 | -21.95 | -28.31 | 37.80 | -161.39 | -109.24 | -149.47 | -9.45 | -11.62K | -11.51K | -18.68K | -8.10K | -2.81K |
| Weighted Avg Shares Out | 65.83M | 76.74M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 778.78K | 295.27K | 321.72K | 320.39K | 318.82K | 301.31K | 271.84K | 244.16K | 234.90K | 187.82K | 129.48K | 2.50K | 2.09K | 1.04K | 2.60K | 2.60K |
| Weighted Avg Shares Out (Dil) | 65.83M | 75.69M | 30.64M | 19.18M | 12.00M | 11.21M | 3.42M | 778.78K | 295.27K | 321.72K | 320.39K | 318.82K | 301.31K | 287.15K | 244.16K | 234.90K | 187.82K | 129.48K | 2.50K | 2.09K | 1.04K | 2.60K | 2.60K |
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ: GYRE)...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Gyre Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gyre Therapeutics, Inc. ("Gyre" or "the Company") (NASDAQ:GYRE) for...
Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
EMERYVILLE, Calif. , Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D.
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
Korro Bio is working on an RNA-editing platform, and its stock price shot up 171% in November. Gyre Therapeutics is a commercial-stage drugmaker in China that could expand into the lucrative U.S. market.
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (NASDAQ: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver diseases, today announced the presentation of a poster at the American Association for the...
Source: https://incomestatements.info
Category: Stock Reports